

1 Modified recipe to inhibit GSK-3 for the living fungal 2 biomaterial manufacture

3 Jinhui Chang^{1¶}, Po Lam Chan^{1¶}, Yichun Xie¹, Man Kit Cheung¹, Ka Lee Ma¹, Hoi Shan
4 Kwan^{1*}

5 ¹ School of Life Sciences, The Chinese University of Hong Kong, Shatin, New Territories,
6 Hong Kong

7 *Corresponding author: E-mail: hskwan@eservices.cuhk.edu.hk

8 ¶These authors contributed equally to this work.

9

10

11

12 **Abstract**

13 Living fungal mycelium with suppressed or abolished fruit-forming ability is a self-healing
14 substance particularly valuable biomaterial for further engineering and development in
15 applications such as monitoring/sensing environmental changes and secreting signals. The
16 ability to suppress fungal fruiting is also a useful tool for maintaining stability (*e.g.*, shape,
17 form) of a mycelium-based biomaterial with ease and lower cost.

18 The objective of this present study is to provide a biochemical solution to regulate the fruiting
19 body formation to replace heat killing of mycelium during production. We discovered that
20 GSK-3 activity directly correlates with the development of fruiting bodies in fungi, especially
21 mushroom forming fungi such as *Coprinopsis cinerea*. By regulating GSK-3 expression and
22 activity, one can control the fungal fruiting body development.

23 We successfully demonstrated that treatment of an inhibitor of GSK-3 kinase activity resulted
24 in acceleration in mycelium growth rate, absence of fruiting body and general decrease in
25 GSK-3 gene expression. Therefore, GSK-3 inhibitor is suggested to be included in the
26 mycelium cultivation recipes for regulating the growth of fungal mycelium and for inhibiting
27 the development of fruiting bodies. This is the first report of using a GSK-3 inhibitor, such as
28 lithium or any other GSK-3 inhibitor, to suppress or abolish fruiting body formation in living
29 fungal mycelium-based biomaterial. It also provides an innovative strategy for easy, reliable,
30 and low cost maintenance of biomaterial containing live fungal mycelium.

31

32

33 **Introduction**

34 Fungal mycelium-based biomaterials are fast emerging in recent years. Mycelium is the
35 vegetative structure of fungi, mainly composed of natural polymers. Mycelium-based
36 biomaterials have a wide range of applications due to their controlled and tunable properties
37 during growth, its self-assembly, self-healing, environmentally responsive, and biodegradable
38 nature. The dried mycelium has strength, durability, and many other beneficial qualities: it is
39 nontoxic, fire-resistant, mold resistant, water-resistant, and a great thermal insulator, amongst
40 other salient features(1–13). Under proper circumstances, mycelium of many mushroom-
41 forming fungi will aggregate to form mushrooms, which are the fruiting body spreading
42 spores(14). Not only the fruiting bodies will cause conformational changes of the mycelium
43 based materials, but also the spores may cause allergy and infection in susceptible population.
44 In current production procedures of the mycelium-based materials, whole material are heated
45 or treated with fungicide to kill the living cells, to stop the fruiting body formation(15). Such
46 rendered mycelium-based materials retain few of the benefits of living material. Therefore,
47 new approaches are needed for inhibiting fruiting body formation while keeping the
48 mycelium alive, in order to produce living mycelium-based materials of desirable qualities.

49 Kinases mediate cellular and developmental responses to growth factors, environmental
50 signals, and internal processes, and the kinases cascades play crucial roles in many signaling
51 transduction pathways(16,17). Phosphorylation of proteins kinases affects their activity,
52 localization, stability, conformation, and protein-protein interaction. One interesting and
53 putatively central regulatory kinase is glycogen synthase kinase-3 (GSK-3). GSK-3 is a
54 serine/ threonine kinase of the CMGC family of proline-directed kinases that is highly
55 conserved in all eukaryotes. GSK-3 is activated by the constitutive phosphorylation at a C-
56 terminal tyrosine residue, however, the regulatory phosphorylation at an N-terminal serine

57 residue causes a conformational change to block the catalytic domain, hence inhibits its
58 kinase activity (18). The kinases PKA, PKB, and PKC inhibit GSK-3 in specific signaling
59 pathways in eukaryotes, while in fungi these kinases are essential growth regulators in
60 response to environmental stimuli(19–21).

61 In mammals, GSK-3 inhibition has attracted widespread attention as one of the critical
62 therapeutic targets whereby lithium exerts its pharmacological effects on mood stabilization,
63 neurogenesis, neurotrophicity, neuroprotection, anti-inflammation, and others(18). Lithium
64 compounds are also suggested to be added in cultivation to fortify the lithium nutrient value
65 of some edible mushrooms (22,23). Lithium chloride (LiCl) is a well-known substance that
66 has been shown to inhibit GSK-3 and recent evidence suggests that low, non-toxic
67 concentrations of such a compound have indeed anti-inflammatory effects(24).

68 In this study, *Coprinopsis cinerea* is used to represent the white-rot basidiomycetous fungi, as
69 it is a classic model mushroom-forming fungus(25). The typical life cycle of *C. cinerea* can
70 be finished within 2 weeks under lab condition, which includes stages of basidiospores,
71 vegetative mycelium, hyphal knots, initial, stage-1 and -2 primordia, young and mature
72 fruiting bodies(26).

73 This study aims to provide a biochemical approach to inhibit fruiting body formation from
74 the mycelium-based biomaterials, thus producing living biomaterials. We demonstrated that
75 fruiting body development in mushrooms can be regulated by modulating GSK-3 expression
76 and/or activity: suppression of GSK-3 expression and/or activity can promote the growth of
77 mycelium and inhibit the fruiting body formation, whereas enhancement of GSK-3
78 expression and/or activity can achieve opposite effects. Regulation of GSK-3 can be applied
79 in the manufacturing of mycelium-based biomaterials, which can shorten the production

80 cycle, reduce the cost for maintenance of mycelium materials, and therefore achieve a higher
81 level of cost-effectiveness.

82 **Materials and Methods**

83 **Strains and cultivation conditions**

84 Two GSK3 inhibitors (LiCl and CHIR99021-HCl) and one GSK3 activator (Cisplatin) were
85 tested in *Coprinopsis cinerea*, the homokaryotic fruiting strain #326 (*A43mut B43mut pab1-*
86 *I*). One GSK3 inhibitor (LiCl) was tested in *Pleurotus djamor* (commonly known as the pink
87 oyster mushroom). Belonging to the same order Agaricales, these two tested mushroom
88 species are of two different families, Psathyrellaceae and Pleurotaceae, respectively. *C.*
89 *cinerea* is cultured on yeast extract-malt extract-glucose (YMG) agar plates (per litre, 4 g
90 yeast extract; 10 g malt extract; 4 g glucose; 10 g agar;) at 37°C in the dark until mycelia
91 grow over the whole agar surface (27). Fruiting body development is induced by incubating
92 the mycelia at 25°C under a 12hours light /12hours dark cycle. *P. djamor* is cultivated on
93 Potato Dextrose Agar (PDA, BD Difco™) plates at 28 °C in the dark until mycelia grow over
94 the whole agar surface, and transferred to 25 °C 12hours light /12hours dark cycle to induce
95 fruiting body formation. Triplicates were employed in each set up. Each plate was measured
96 for 45g (±1g) medium to uniform the nutrients contents and for accurate inhibitor
97 concentration.

98 **Effect of Inhibitors and Activator**

99 Inhibitors of GSK-3 used in this study include lithium chloride (LiCl), as well as CHIR99021
100 trihydrochloride. Three methods have been tested to deliver LiCl (Sigma-Aldrich, St. Louis,
101 MO, USA). One delivery method is to mix 1.5g/L, 3 g/L or 6g/L LiCl in the medium before

102 autoclave sterilization, and the other methods are to spread LiCl solution on the surface of
103 agar before inoculation, or add LiCl solution under the agar after mycelia reaches the petri
104 dish edge. CHIR99021 trihydrochloride is very specific and water soluble, so it is used to
105 confirm the effect of inhibited GSK-3 on fruiting body development. 5nM, 10nM and 15nM
106 of CHIR99021 trihydrochloride is spread on the surface of agar evenly before inoculation.

107 In this study, one specific GSK-3 activator, cisplatin, is tested. It is also known as
108 cisplatinum, platamin, neoplatin, cismaplat, or cis-diamminedichloridoplatinum(II) (CDDP),
109 a chemical most commonly used in chemotherapy in cancer treatment. 1 ml Water or
110 saturated Cisplatin solution (25 °C) was filtered and spread on the surface of YMG agar,
111 before inoculation. CHIR99021 trihydrochloride and cisplatin are not suggested to be
112 autoclaved, so we use 0.2 micron filter to remove all bacteria in the solution.

113 **Sensitive window to LiCl**

114 The effect of LiCl at different developmental stages of *C. cinerea* are tested to find the
115 sensitive window. 0.1ml of 3g/L LiCl or 0.1 ml water were added under the agar at the
116 stages of: mycelium, hyphal knot, initial, stage-1primordium, stage-2 primordium and young
117 fruiting body. The growth status was record till 3 days after the control group form mature
118 fruiting bodies.

119 **Expression levels of GSK-3 downstream target genes**

120 The expression levels of targets genes of GSK-3 were measured to explore the mechanism of
121 LiCl. The GSK-3 downstream targets were predicted by Orthologue comparison. A total of
122 83 GSK-3 downstream targets reported in human and mouse, were compared to the *C.*
123 *cinerea* genes by OrthoMCL V2.0 (28), and 52 orthologues were identified. Among them,

124 glycogen synthase (CC1G_01973), GSK-3 (CC1G_03802), eukaryotic translation initiation
125 factor 1 (eIF1) (CC1G_03881), uncharacterized protein with Ricin B-type lectin domain
126 (CC1G_05298), translation initiation factor eIF2 gamma subunit (CC1G_09429) were picked
127 for real-time PCR analysis. For each gene, primers for two segments with similar PCR
128 condition were selected.

129 Samples treated by water or 1.5g/L or 3g/L LiCl (mixed before autoclave) were cultured as
130 conditions described above. Once the control group started fruiting body initiation, total RNAs
131 of three biological replicates were extracted using RNeasy® Plant Mini Kit (Qiagen). RNA
132 products were stored at -80°C. The concentration of RNA was measured by NanoDrop
133 Spectrophotometers (Thermo Scientific). 500ng RNA products were used to synthesize cDNA
134 using iScript™ cDNA Synthesis Kit (Bio-Rad). Quantitative real-time PCR (qPCR) was
135 performed by Applied Biosystems® 7500/7500 Fast Real-Time PCR system™ (Applied
136 Biosystems) using iQTM SYBR® Green Supermix (Bio-Rad).

137 **Results**

138 **Effect of GSK-3 inhibitors and activator on fruiting body**

139 **development**

140 As shown in Figure 1a, effect of LiCl to *C. cinerea* fruiting body development was tested.

141 While the control group has already developed into mature fruiting bodies, primordium,

142 initials and hyphal knots were formed on the plates treated with 1.5g/L LiCl respectively.

143 The plates treated with 3g/L LiCl and 6g/L LiCl were arrested in mycelium stage, and

144 mycelium treated with 6g/L LiCl grew than other groups. These results showed that LiCl of

145 higher concentrations have stronger inhibitory effect on *C. cinerea* fruiting body

146 development.

147 The three delivery methods of LiCl, either mixed in the agar, on the surface of agar, or under

148 the agar, show no differences and all can efficiently inhibit the fruiting body development.

149 LiCl is not sensitive to heat treatment, and can be autoclaved to sterilize the solution. Any of

150 these delivery methods can be chosen in a large-scale manufacture of the biomaterials.

151 In order to confirm that the inhibition of fruiting body development is caused by GSK-3

152 inhibition, another more specific GSK-3 inhibitor, CHIR99021 trihydrochloride, was tested.

153 As shown in 1b, Young fruiting bodies developed on the control plates treated with water and

154 the plates with 1 μ M CHIR99021 trihydrochloride. The plates treated with 100 μ M

155 CHIR99021 trihydrochloride developed primordium. The plates treated with 500 μ M

156 CHIR99021 trihydrochloride remained arrested in mycelium stage. These results showed an

157 stronger inhibitory effect on *C. cinerea* fruiting body development by CHIR99021

158 trihydrochloride at higher concentrations.

159 LiCl and CHIR99021 trihydrochloride treatments inhibited the fruiting body initiation in a
160 dose-dependent manner (Figure 1a and 1b). Given that both LiCl and CHIR99021
161 trihydrochloride are specific inhibitors to GSK-3, it can be concluded that the effect of
162 lithium is mediated through the inhibition of GSK-3 activity.

163 To demonstrate that GSK-3 is also important in fruiting body formation in other mushrooms,
164 the effect of LiCl to *Pleurotus djamor* fruiting body development was tested (Figure 1c). *C.*
165 *cinerea* and *P. djamor* are two fungal species within the same family of Basidiomycota and
166 the same order of Agaricales.

167 LiCl was added to YMG agar medium before autoclave. Mature fruiting bodies developed
168 on the control plates. The plates treated with 2g/L LiCl failed to develop fruiting body in the
169 following 30 days. These results showed an inhibitory effect on *P. djamor* fruiting body
170 development by LiCl.

171 With the positive results that GSK-3 inhibitor can inhibit the fruiting body development, it is
172 hypothesized that GSK-3 activity is associated with the fruiting body development. Then a
173 GSK-3 activator, cisplatin, was tested for its effect on *C. cinerea* fruiting body development
174 (Figure 1d). The activator treated group with 1 ml saturated Cisplatin, showed an accelerated
175 development since the formation of hyphal knot, and the mature fruiting body appeared 2
176 days earlier than the control group, while the control group was slower and only developed
177 into young fruiting body. These results showed a positive or promoting effect on *C. cinerea*
178 fruiting body development by GSK-3 activator, Cisplatin.

179

180 **Fig. 1 Effect of GSK-3 inhibitors and activator on the fruiting body development. (a)**The
181 different doses of GSK-3 inhibitor, LiCl, have different levels of inhibitory effect on the

182 development of *C. cinerea*. Mature fruiting bodies, young fruiting bodies, primordia and
183 initials were produced in the control group, while the 1.5g/L LiCl treated group produced only
184 initials and primordia. No initiation was observed in the groups treated with higher
185 concentration of LiCl, in the following 30 days. **(b)** The different doses of GSK-3 inhibitor,
186 CHIR99021 trihydrochloride, have different levels of inhibitory effect on the development of
187 *C. cinerea*. Young fruiting bodies developed in the control group and 1 μ M treated group,
188 while only primordium were developed on plates treated with 100 μ M. The plates treated
189 with 500 μ M remained in mycelium stage in the following 30 days. **(c)** GSK-3 inhibitor,
190 LiCl, also inhibit he development of *P. djamor*. Mature fruiting bodies, young fruiting
191 bodies, primordia and initials were produced in the control group, while the 2g/L LiCl
192 remained in mycelium stage in the following 30 days. **(d)** GSK-3 activator, cisplatin,
193 accelerates the development of *C. cinerea*. After 6-days incubation, the plates treated with 1
194 ml saturated Cisplatin solution had fruiting body and began autolysis, while the control group
195 was slower and only developed into young fruiting body.

196

197 These data unequivocally support the conclusion that among fungus species of the division
198 Basidiomycota, especially of the order Agaricales, GSK3 inhibitors inhibit/reduce/decelerate
199 the fruiting body formation, whereas GSK3 enhancers activate/increase/accelerate the
200 fruiting body formation.

201 **GSK-3 inhibitor promotes mycelium growth**

202 The mycelial growth rate was measured for the LiCl treated *C. cinerea*. Biological triplicates
203 were cultivated on YMD at 38°C in darkness, treated with different doses of LiCl. The
204 mycelium area was recorded for 4 days. Figure 2a shows the average growth area of each

205 group. As the inoculum usually need time to adapt to the new environment and absorb
206 nutrients, there was no differences on the first two days. The differences appear on the 3rd day,
207 the LiCl treated groups spanned faster than the control group, and after 144 hours of
208 inoculation the mycelium spanned into a circle shape of 51.8 cm² for 1.5g/L, and 55.1 cm² for
209 3 g/L, while 42.9 cm² for control group. The results show that proper concentrations of LiCl
210 can accelerate the mycelium growth.

211 This is an ideal property of GSK-3 inhibitor for the large-scale manufacture of mycelium-
212 based biomaterial. The modified recipe with addition of proper concentration of LiCl, can not
213 only inhibit the appearance of fruiting body, but also speed up the mycelium growth, and
214 hence lower the shorten the manufacture cycle and lower the cost.

215 **Effect of GSK-3 inhibitor on gene expression levels**

216 To validate the LiCl is targeting on GSK-3 other than other gene, we test the expression
217 levels of the GSK-3 gene and its downstream target genes. Two segments of each gene were
218 tested for higher accuracy. The real-time PCR results show that the LiCl could regulate the
219 expression of the GSK-3 gene itself, as well as the selected GSK-3 target genes. GSK-3,
220 glycogen synthase, and protein with Ricin B-type lectin domain showed decrease in gene
221 expression levels with increase of LiCl concentration. eukaryotic translation initiation factor
222 1 is stable in all conditions, while translation initiation factor eIF2 gamma subunit increase to
223 2-fold in 1.5g/L LiCl treated group. The change in gene expression supports that LiCl targets
224 the GSK-3 and affects its downstream genes.

225

226 **Fig. 2 (a)** Mycelial growth of *C. cinerea* with different doses of LiCl, biological triplicates
227 were used for mean calculation. The growth rate of mycelium treated with 1.5g/L and 3g/L

228 LiCl is higher than control. **(b)**The gene expression levels are indicated by the abundance of
229 segments on the cDNA, by real-time PCR. The GSK-3 and its target genes change the
230 expression level under LiCl treatment. 1973-1 & 1973-2 are two segments on the cDNA of
231 glycogen synthase (CC1G_01973), and the others are segments of the following transcripts:
232 GSK-3 (CC1G_03802); eukaryotic translation initiation factor 1 (CC1G_03881);
233 Uncharacterized protein with Ricin B-type lectin domain (CC1G_05298); Translation
234 initiation factor eIF2 gamma subunit (CC1G_09429).

235 **Sensitive Window to GSK-3 inhibitor LiCl**

236 For the current manufacture of mycelium-base biomaterial, it's difficult to avoid the
237 formation of fruiting body. Upon environmental stimuli, including nutrient depletion,
238 light/dark cycle, and cold shock, mycelia aggregate into hyphal knot, followed by fruiting
239 body initials. Initials then develop into stage-1 and -2 primordia, young and mature fruiting
240 bodies. The companies may already have fixed production line, so we want to explore all the
241 possible procedures to introduce the GSK-3 inhibitor, specifically, LiCl, which is cheaper
242 compared to other GSK-3 inhibitors.

243 In the previous sections, LiCl is demonstrated to arrest the mycelium. Hyphal knot is a short
244 stage which is difficult to define by naked eyes. So we only test the stages after initials. As
245 shown in Figure 3a, adding 3g/L LiCl at stages of initial and stage-1 primordium led to the
246 arrest of their development, while stage-2 primordium and young fruiting body could
247 continue to develop into mature fruiting bodies. Intervention of LiCl at stages of mycelium,
248 initial and stage-1 primordium resulted in arrestment in fruiting body development, so these
249 stages are sensitive windows to LiCl.

250

251 **Fig. 3 (a)**The development of *C. cinerea* treated with 0.1ml of 3g/L LiCl at different stage.

252 Adding 3g/L LiCl at stages of initial and stage-1 primordium led to inhibition on further
253 development. Adding 3g/L LiCl at stages of stage-2 primordium and young fruiting body
254 cannot inhibit the fruiting body development. **(b)** Proposed procedures of the production
255 pipeline of living mycelium-based materials, and the GSK-3 inhibitors can be added at any
256 time from procedure 1 to 7.

257

258 For producing living mycelium-based material, the basic production pipeline is designed for
259 adding GSK-3 inhibitors, particularly the lithium or lithium salt. The production pipeline can
260 be all of part of the following procedures: 1) substrates mixing and autoclave; 2) inoculation;
261 3) mycelium 1st growth; 4) molding and pressurize; 5) mycelium 2nd growth; 6) pressurize
262 (optional); 7) mycelium 3rd growth (optional); 8) air-dry to finalized product. LiCl or other
263 GSK-3 inhibitors can be added at any time from procedure 1) to 7), by mixing in the
264 substrate before autoclave, adding the sterilized solution on the surface or inside the medium
265 mixture before inoculation, or spraying to the mycelium after a period of growth.

266 **Discussion**

267 The study demonstrated that GSK-3 activity can determine the fruiting body development,
268 and GSK-3 inhibitor is suggested to be included into recipes to manufacture live fungal
269 mycelium that exhibits an altered and more desirable profile of fruiting body development as
270 well as compositions that contain the fungal mycelium.

271 In many instances one would prefer for a live fungal mycelium to refrain from developing
272 fruiting bodies such that the mycelium is easily maintained without concerns of loss in its
273 shape, form, or consistency. In contrast to the currently-in-use method of heat-killing fungal

274 mycelium to prevent fruiting body formation, a live version of mycelium that simply does not
275 form fruiting bodies is far more desirable considering its live nature and thus healing
276 potential.

277 In other cases, promoting fruiting body development may be of interest. For instance, when
278 the intended goal is to produce and harvest as many fruiting bodies (*e.g.*, mushrooms and
279 truffles) as possible in a defined time period, having enhanced fruiting body development is
280 beneficial.

281 Glycogen synthase kinase-3, GSK-3 has important role in cell-fate specification, leading to
282 cell differentiation or apoptosis or development through number of signaling pathways(29–
283 32). So we propose a pathway that GSK-3 could be the links between environmental stimuli
284 and the responsive development, and a master-switch of fruiting body formation (Figure 4).

285

286 **Fig. 4: Glycogen synthase kinase-3 (GSK-3) as a master-switch of fruiting body**

287 **formation.** GSK-3 has important role in cell-fate specification, leading to cell differentiation
288 or apoptosis or development through number of signaling pathways. GSK-3 could be the
289 links between environmental stimuli and the responsive development, and a master-switch of
290 fruiting body formation. The activity of GSK-3 determines the fruiting body development.

291

292 For producing a live fungal mycelium with an enhanced or inhibited fruiting body
293 development profile, either a permanent means (*e.g.*, GSK-3 knockdown or GSK-3 knockout
294 fungal strain) or a transient means (*e.g.*, application of an activator or inhibitor of GSK-3
295 present in the medium for fungi) can be employed. While the former may be easier to
296 maintain in the long term, efforts involved in the initial stage of establishing the genetically

297 modified fungal strains are tremendously more significant both in cost and in time. In
298 contrast, the latter offers the benefits of flexibility and low-cost use, when the GSK-3
299 activator or inhibitor can be readily removed at an appropriate time such that the fungus may
300 resume its normal life cycle of different phases.

301 One possibility is to reduce or abolish GSK-3 expression by genetic manipulation of the
302 fungal cells' genomic sequence encoding the GSK-3 protein or by transient or permanent
303 expression of small inhibitory RNAs. The gene encoding GSK-3 is highly conserved across
304 diverse phyla. It is a serine/threonine kinase having a monomeric structure and a size of
305 approximately 47 kilo daltons. The amino acid sequence and corresponding polynucleotide
306 coding sequence for *C. cinerea* GSK-3 are provided in GenBank Accession Numbers
307 XP_001833585 (strain okayama7#130) and NW_003307543.1 (Genomic Sequence in strain
308 Okayama7#130) / jgi|Copci_AmutBmut1|363162|e_gw1.29.187.1 (in strain #326, Taxonomy
309 ID: 1132390 and Accession: PRJNA258994), respectively. The GSK-3 is highly conserved
310 in protein sequence. The homologous proteins include PIL30457.1 in *Ganoderma sinense*
311 ZZ0214-1, and jgi|Gansp1|158466|gm1.11165_g in *Ganoderma* sp. 10597 SS1 (North
312 American isolate of *G. lucidum*), and KDQ33621 in *Pleurotus ostreatus* PC15. As used
313 herein, a GSK-3 protein encompasses both *C. cinerea* GSK-3 protein and its
314 homologs/orthologs in fungal species, especially those of Basidiomycota, having at least 90%
315 or more sequence homology to *C. cinerea* GSK-3 protein sequence and share essentially the
316 same biological or enzymatic activity.

317 A GSK-3 knockdown cell may be generated by genetic manipulation of the genomic GSK-3
318 sequence of a suitable parent cell. Methods such as sequence homology-based gene
319 disruption methods utilizing a viral vector or CRISPR system can be used for altering the
320 GSK-3 genomic sequence, for example, by insertion, deletion, or substitution, which may

321 occur in the coding region of the gene or in the non-coding regions (*e.g.*, promoter region or
322 other regulatory regions) and which may result in complete abolition of GSK-3 expression,
323 reduced GSK-3 expression, or unaltered expression at mRNA level but diminished GSK-3
324 protein activity.

325 Another possibility is to suppress the activity of endogenously expressed GSK-3 protein by
326 introducing a GSK-3 inhibitor into the external environment in which the fungi grow.

327 Lithium salts have mycelium-enhancing effect to some mushroom forming fungi, but the
328 concentration range of such effect is narrow. In some other mushroom forming fungi, high
329 concentration of LiCl may inhibit the mycelium growth, especially in *Trichoderma* species,
330 which is a common contamination of the edible mushroom (33). Thus, while LiCl might be
331 applied to prevent fruiting in some mushroom-forming fungi, it can also inhibit the
332 contamination during manufacturing in some scenario. In addition to LiCl, other agents that
333 specifically target GSK-3, can also prevent the development of fruiting body. In support of
334 this conclusion, CHIR99021 trihydrochloride, an alternative GSK-3 specific inhibitor that
335 acts through a distinct mechanism, also inhibits fruiting body formation. Other known GSK-3
336 inhibitors include: Maleimide Derivatives; Staurosporine and Organometallic Inhibitors;
337 Indole Derivatives; Paullone Derivatives; Pyrazolamide Derivatives; Pyrimidine and
338 Furopyrimidine Derivatives; Oxadiazole Derivatives; Thiazole Derivatives; and
339 Miscellaneous Heterocyclic Derivatives. (18,34)

340

341 The sensitive window to LiCl is from mycelium, hyphal knot, initial to stage-1 primordium.
342 This indicates that the LiCl may inhibit fruiting through affecting the cell differentiation.
343 Inhibitors of GSK-3 were shown to maintain the mouse and human embryonic stem (ES)
344 cells in undifferentiated status, while removing inhibitor promotes differentiation into

345 multiple cell lineages (35). The potency maintaining function of GSK-3 may be related to
346 protein degradation. After phosphorylated by GSK-3, many substrates will then be targeted
347 by ubiquitination for proteasome-mediated degradation. Undifferentiated cells are
348 proliferative because GSK-3 activity is limited by persistent unfavorable growing condition
349 signals. The effectors of GSK-3, such as transcription factors, are less modified by
350 phosphorylation and ubiquitination, so their half-lives are prolonged to enhance
351 stem/precursor cell proliferation (36). This suggested GSK3 interferes fruiting by interfering
352 cell specification. Deeper studies are needed to discover the mechanism in detail.

353

354 Reference

- 355 1. Jones M, Bhat T, Huynh T, Kandare E, Yuen R, Wang CH, et al. Waste-derived low-
356 cost mycelium composite construction materials with improved fire safety. *Fire and*
357 *Materials*. 2018 Nov;42(7):816–25.
- 358 2. Nguyen PQ, Courchesne NMD, Duraj-Thatte A, Praveschotinunt P, Joshi NS.
359 *Engineered Living Materials: Prospects and Challenges for Using Biological Systems*
360 *to Direct the Assembly of Smart Materials*. Vol. 30, *Advanced Materials*. 2018. p.
361 1704847.
- 362 3. Karana E, Blauwhoff D, Hultink E, Camere S. When the Material Grows : A Case
363 Study on Designing (with) Mycelium-based Materials. 2018;12(2):119–36.
- 364 4. Nguyen PQ, Courchesne NMD, Duraj-Thatte A, Praveschotinunt P, Joshi NS.
365 *Engineered Living Materials: Prospects and Challenges for Using Biological Systems*
366 *to Direct the Assembly of Smart Materials*. Vol. 30, *Advanced Materials*. 2018.
- 367 5. Grimm D, Wösten HAB. Mushroom cultivation in the circular economy. Vol. 102,
368 *Applied Microbiology and Biotechnology*. 2018. p. 7795–803.
- 369 6. Appels FVW, Dijksterhuis J, Lukasiewicz CE, Jansen KMB, Wösten HAB, Krijgsheld
370 P. Hydrophobin gene deletion and environmental growth conditions impact
371 mechanical properties of mycelium by affecting the density of the material. *Scientific*
372 *Reports*. 2018;8(1).
- 373 7. Camere S, Karana E. Fabricating materials from living organisms: An emerging design
374 practice. *JOURNAL OF CLEANER PRODUCTION*. 2018;186:570–84.

- 375 8. Khamrai M, Banerjee SL, Kundu PP. A sustainable production method of mycelium
376 biomass using an isolated fungal strain *Phanerochaete chrysosporium* (accession no:
377 KY593186): Its exploitation in wound healing patch formation. *Biocatalysis and*
378 *Agricultural Biotechnology*. 2018;16:548–57.
- 379 9. Jones M, Bhat T, Huynh T, Kandare E, Yuen R, Wang CH, et al. Waste-derived low-
380 cost mycelium composite construction materials with improved fire safety. *Fire and*
381 *Materials*. 2018;
- 382 10. Kilaru S, Hoegger PJ, Kües U. The laccase multi-gene family in *Coprinopsis cinerea*
383 has seventeen different members that divide into two distinct subfamilies. *Current*
384 *Genetics*. 2006 Jul 28;50(1):45–60.
- 385 11. Grimm D, Wösten HAB. Mushroom cultivation in the circular economy. Vol. 102,
386 *Applied Microbiology and Biotechnology*. 2018. p. 7795–803.
- 387 12. Appels FVW, Camere S, Montalti M, Karana E, Jansen KMB, Dijksterhuis J, et al.
388 Fabrication factors influencing mechanical, moisture- and water-related properties of
389 mycelium-based composites. *Materials & Design*. 2018;
- 390 13. Silverman J. Development and testing of mycelium-based composite materials for
391 shoe sole applications. 2018;
- 392 14. Kües U, Subba S, Yu Y, Sen M. Regulation of fruiting body development in
393 *Coprinopsis cinerea*. 2016;(July).
- 394 15. Haneef M, Ceseracciu L, Canale C, Bayer IS, Heredia-Guerrero JA, Athanassiou A.
395 *Advanced Materials From Fungal Mycelium: Fabrication and Tuning of Physical*
396 *Properties*. *Scientific Reports*. Nature Publishing Group; 2017;7(January):41292.

- 397 16. Kosti I, Mandel-Gutfreund Y, Glaser F, Horwitz B. Comparative analysis of fungal
398 protein kinases and associated domains. *BMC Genomics*. 2010 Feb;11(1):133.
- 399 17. Wang C, Zhang S, Hou R, Zhao Z, Zheng Q, Xu Q, et al. Functional analysis of the
400 kinome of the wheat scab fungus *Fusarium graminearum*. Howlett BJ, editor. *PLoS*
401 *pathogens*. Public Library of Science; 2011 Dec;7(12):e1002460.
- 402 18. Takahashi-yanaga F. Activator or inhibitor ? GSK-3 as a new drug target. *Biochemical*
403 *Pharmacology*. Elsevier Inc.; 2013;86(2):191–9.
- 404 19. Andoh T, Hirata Y, Kikuchi A. Yeast glycogen synthase kinase 3 is involved in
405 protein degradation in cooperation with Bull1, Bul2, and Rsp5. *Molecular and cellular*
406 *biology*. 2000 Sep;20(18):6712–20.
- 407 20. Moore SF, van den Bosch MTJ, Hunter RW, Sakamoto K, Poole AW, Hers I. Dual
408 regulation of glycogen synthase kinase 3 (GSK3) α/β by protein kinase C (PKC) α and
409 Akt promotes thrombin-mediated integrin α IIb β 3 activation and granule secretion in
410 platelets. *The Journal of biological chemistry*. 2013 Feb 8;288(6):3918–28.
- 411 21. Tataroğlu Ö, Lauinger L, Sancar G, Jakob K, Brunner M, Diernfellner ACR. Glycogen
412 synthase kinase is a regulator of the circadian clock of *Neurospora crassa*. *The Journal*
413 *of biological chemistry*. 2012 Oct 26;287(44):36936–43.
- 414 22. Mleczek M, Siwulski M, Rzymiski P, Budzyńska S, Gąsecka M, Kalač P, et al.
415 Cultivation of mushrooms for production of food biofortified with lithium. *European*
416 *Food Research and Technology*. 2017;243(6):1097–104.

- 417 23. De Assunção LS, Da Luz JMR, Da Silva MDCS, Vieira PAF, Bazzolli DMS, Vanetti
418 MCD, et al. Enrichment of mushrooms: An interesting strategy for the acquisition of
419 lithium. *Food Chemistry*. Elsevier; 2012 Sep 15;134(2):1123–7.
- 420 24. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of
421 glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for
422 autoregulation of GSK-3. *The Journal of biological chemistry*. American Society for
423 Biochemistry and Molecular Biology; 2003 Aug 29;278(35):33067–77.
- 424 25. Stajich JE, Wilke SK, Ahrén D, Hang C, Birren BW, Borodovsky M, et al. Insights
425 into evolution of multicellular fungi from the assembled chromosomes of the
426 mushroom *Coprinopsis cinerea* (*Coprinus cinereus*).
- 427 26. Plaza D, Lin C-W, van der Velden NS, Aebi M, Künzler M, Dacks J, et al.
428 Comparative transcriptomics of the model mushroom *Coprinopsis cinerea* reveals
429 tissue-specific armories and a conserved circuitry for sexual development. *BMC*
430 *Genomics*. BioMed Central; 2014;15(1):492.
- 431 27. Rao PS, Niederpruem DJ. Carbohydrate metabolism during morphogenesis of
432 *Coprinus lagopus* (sensu Buller). *Journal of bacteriology*. 1969 Dec;100(3):1222–8.
- 433 28. Li L, Stoeckert CJ, Roos DS. OrthoMCL: identification of ortholog groups for
434 eukaryotic genomes. *Genome research*. Cold Spring Harbor Laboratory Press; 2003
435 Sep 1;13(9):2178–89.
- 436 29. Tataroglu O. Role of Glycogen Synthase Kinase (GSK) in temperature compensation
437 of the. 2011;1–88.

- 438 30. Ninkovic J, Stigloher C, Lillesaar C, Bally-Cuif L. Gsk3beta/PKA and Gli1 regulate
439 the maintenance of neural progenitors at the midbrain-hindbrain boundary in concert
440 with E(Spl) factor activity. *Development (Cambridge, England)*. 2008;135(18):3137–
441 48.
- 442 31. Casas-Flores S, Rios-Momberg M, Rosales-Saavedra T, Martínez-Hernández P,
443 Olmedo-Monfil V, Herrera-Estrella A. Cross Talk between a Fungal Blue-Light
444 Perception System and the Cyclic AMP Signaling Pathway. *Eukaryotic Cell*. 2006
445 Mar;5(3):499–506.
- 446 32. Zanolli F, Magalhães R, Paula D, Carlos L, Barbosa B, Francisco H, et al. cAMP
447 signaling pathway controls glycogen metabolism in *Neurospora crassa* by regulating
448 the glycogen synthase gene expression and phosphorylation. *Fungal Genetics and*
449 *Biology*. Elsevier Inc.; 2010;47(1):43–52.
- 450 33. H.G.Wildman. Lithium chloride as a selective inhibitor of *Trichoderma* species on soil
451 isolation plates. *Mycological Research*. Elsevier; 1991 Dec 1;95(12):1364–8.
- 452 34. Selenica M-L, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, et al. Efficacy
453 of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of
454 tau hyperphosphorylation. *British journal of pharmacology*. Blackwell Publishing;
455 2007 Nov 12;152(6):959–79.
- 456 35. Kirby LA, Schott JT, Noble BL, Mendez DC, Caseley PS, Peterson SC, et al.
457 Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in
458 mouse embryonic stem cells. Cooney AJ, editor. *PloS One*. Public Library of Science;
459 2012 Jan;7(6):e39329.

460 36. Westermarck J. Regulation of transcription factor function by targeted protein
461 degradation: an overview focusing on p53, c-Myc, and c-Jun. *Methods in molecular*
462 *biology* (Clifton, NJ). 2010 Jan;647:31–6.

463

464

Control


available under aCC-BY 4.0 International license.

1.5g/L

3g/L

6g/L

a



b

Control

1uM

100uM

500uM



c

Control


2g/L




d

Control


Cisplatin



a



b



a



b

